<?xml version='1.0' encoding='utf-8'?>
<document id="27106175"><sentence text="Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide."><entity charOffset="110-129" id="DDI-PubMed.27106175.s1.e0" text="Abiraterone Acetate" /><entity charOffset="134-146" id="DDI-PubMed.27106175.s1.e1" text="Enzalutamide" /><pair ddi="false" e1="DDI-PubMed.27106175.s1.e0" e2="DDI-PubMed.27106175.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27106175.s1.e0" e2="DDI-PubMed.27106175.s1.e1" /></sentence><sentence text="Two novel oral drugs that target androgen signaling have recently become available for the treatment of metastatic castration-resistant prostate cancer (mCRPC)"><entity charOffset="33-41" id="DDI-PubMed.27106175.s2.e0" text="androgen" /></sentence><sentence text=" Abiraterone acetate inhibits the synthesis of the natural ligands of the androgen receptor, whereas enzalutamide directly inhibits the androgen receptor by several mechanisms"><entity charOffset="1-20" id="DDI-PubMed.27106175.s3.e0" text="Abiraterone acetate" /><entity charOffset="74-82" id="DDI-PubMed.27106175.s3.e1" text="androgen" /><entity charOffset="101-113" id="DDI-PubMed.27106175.s3.e2" text="enzalutamide" /><entity charOffset="136-144" id="DDI-PubMed.27106175.s3.e3" text="androgen" /><pair ddi="false" e1="DDI-PubMed.27106175.s3.e0" e2="DDI-PubMed.27106175.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27106175.s3.e0" e2="DDI-PubMed.27106175.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27106175.s3.e0" e2="DDI-PubMed.27106175.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27106175.s3.e0" e2="DDI-PubMed.27106175.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27106175.s3.e1" e2="DDI-PubMed.27106175.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27106175.s3.e1" e2="DDI-PubMed.27106175.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27106175.s3.e1" e2="DDI-PubMed.27106175.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27106175.s3.e2" e2="DDI-PubMed.27106175.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27106175.s3.e2" e2="DDI-PubMed.27106175.s3.e3" /></sentence><sentence text=" Abiraterone acetate and enzalutamide appear to be equally effective for patients with mCRPC pre- and postchemotherapy"><entity charOffset="1-20" id="DDI-PubMed.27106175.s4.e0" text="Abiraterone acetate" /><entity charOffset="25-37" id="DDI-PubMed.27106175.s4.e1" text="enzalutamide" /><pair ddi="false" e1="DDI-PubMed.27106175.s4.e0" e2="DDI-PubMed.27106175.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27106175.s4.e0" e2="DDI-PubMed.27106175.s4.e1" /></sentence><sentence text=" Rational decision making for either one of these drugs is therefore potentially driven by individual patient characteristics" /><sentence text=" In this review, an overview of the pharmacokinetic characteristics is given for both drugs and potential and proven drug-drug interactions are presented" /><sentence text=" Additionally, the effect of patient-related factors on drug disposition are summarized and the limited data on the exposure-response relationships are described" /><sentence text=" The most important pharmacological feature of enzalutamide that needs to be recognized is its capacity to induce several key enzymes in drug metabolism"><entity charOffset="47-59" id="DDI-PubMed.27106175.s8.e0" text="enzalutamide" /></sentence><sentence text=" The potency to cause drug-drug interactions needs to be addressed in patients who are treated with multiple drugs simultaneously" /><sentence text=" Abiraterone has a much smaller drug-drug interaction potential; however, it is poorly absorbed, which is affected by food intake, and a large interpatient variability in drug exposure is observed"><entity charOffset="1-12" id="DDI-PubMed.27106175.s10.e0" text="Abiraterone" /></sentence><sentence text=" Dose reductions of abiraterone or, alternatively, the selection of enzalutamide, should be considered in patients with hepatic dysfunction"><entity charOffset="20-31" id="DDI-PubMed.27106175.s11.e0" text="abiraterone" /><entity charOffset="68-80" id="DDI-PubMed.27106175.s11.e1" text="enzalutamide" /><pair ddi="false" e1="DDI-PubMed.27106175.s11.e0" e2="DDI-PubMed.27106175.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27106175.s11.e0" e2="DDI-PubMed.27106175.s11.e1" /></sentence><sentence text=" Understanding the pharmacological characteristics and challenges of both drugs could facilitate decision making for either one of the drugs" /><sentence text="" /></document>